EDTA (ethylenediaminetetraacetic acid) is scientifically validated for the treatment of lead poisoning. It acts as a chelating agent, binding to lead ions in the bloodstream to form a stable, water-soluble complex that can be excreted via the kidneys. The use of EDTA, specifically its calcium disodium form (CaNa₂EDTA), has been established in clinical practice since the 1950s and is included in numerous clinical guidelines, including those from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).

Multiple clinical studies and case series have demonstrated the efficacy and safety of CaNa₂EDTA in reducing blood lead levels and alleviating symptoms of lead toxicity, particularly in cases of moderate to severe poisoning. Its effectiveness has been compared favorably to other chelators such as dimercaprol and succimer (DMSA) for certain indications. Scientific evidence also outlines the risks of improper use, such as the potential for nephrotoxicity if not administered correctly, which further underscores the robust research and clinical experience underlying its use.

In summary, the use of EDTA for lead poisoning is justified by strong scientific evidence, supported by decades of clinical research and widespread acceptance in medical protocols worldwide.